Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 992 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Disorders Clear all
Recruiting Phase 1 Interventional

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

NCT06319872
View directory record Official record
Conditions
Alcohol Use Disorder, Retinal Dystrophies, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
Interventions
Oral disulfiram
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 28, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.

NCT05119127
View directory record Official record
Conditions
Cataract
Interventions
Alcon Vivity toric intra ocular lens
Device
Lead sponsor
Kevin Barber
Other
Eligibility
45 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 28, 2026, 7:32 AM EDT
Terminated No phase listed Observational

Intraocular Pressure During Prone Spinal Surgery

NCT00176722
View directory record Official record
Conditions
Spine Surgery, Vision Impairment
Interventions
table tilt
Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 28, 2026, 7:32 AM EDT
Recruiting No phase listed Observational

Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study

NCT02841553
View directory record Official record
Conditions
Wolfram Syndrome, Diabetes Mellitus, Optic Nerve Atrophy, Deafness, Diabetes Insipidus, Ataxia
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
0 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 28, 2026, 7:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Advanced Spatiomotor Rehabilitation for Navigation in Blindness & Visual Impairment

NCT05377853
View directory record Official record
Conditions
Blindness, Blindness, Acquired, Low Vision, Blindness, Complete
Interventions
Cognitive-Kinesthetic Navigational Training
Behavioral
Lead sponsor
Smith-Kettlewell Eye Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 28, 2026, 7:32 AM EDT
Not listed No phase listed Observational

Eye Movement Rehabilitation in Low Vision Patients

NCT04929756
View directory record Official record
Conditions
Low Vision, Age Related Macular Degeneration
Interventions
Visual Feedback
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
14 Years to 99 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 28, 2026, 7:32 AM EDT
Completed Not applicable Interventional

The Role of Music in Enhancing Attention During Visual Field Exams for Pediatric Glaucoma Patients

NCT06971588
View directory record Official record
Conditions
Glaucoma
Interventions
Music intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 28, 2026, 7:32 AM EDT
Completed Phase 1 Interventional

Cilengitide in Treating Children With Refractory Primary Brain Tumors

NCT00063973
View directory record Official record
Conditions
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
cilengitide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 28, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

NCT06349759
View directory record Official record
Conditions
Mesopic Vision, Night Vision Loss
Interventions
phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, Placebo
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
25
States / cities
Pheonix, Arizona • Scottsdale, Arizona • Bakersfield, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 7:32 AM EDT
Recruiting Phase 3 Interventional

A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

NCT07710196
View directory record Official record
Conditions
Retinitis Pigmentosa (RP), Usher Syndrome
Interventions
Placebo, NPI-001
Drug
Lead sponsor
Nacuity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 7:32 AM EDT
Completed No phase listed Observational

Eeva™ System Study: Noninvasive Recording and Visualization of Individual Embryos Cultured to Blastocyst Stage

NCT01369446
View directory record Official record
Conditions
Infertility
Interventions
Eeva System Study
Device
Lead sponsor
Progyny, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Encino, California • Palo Alto, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 28, 2026, 7:32 AM EDT
Terminated Not applicable Interventional Results available

18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas

NCT02175745
View directory record Official record
Conditions
Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Recurrent Adult Brain Tumor, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Diffuse Astrocytoma, Recurrent Childhood Fibrillary Astrocytoma, Recurrent Childhood Gemistocytic Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Oligoastrocytoma, Recurrent Childhood Oligodendroglioma, Recurrent Childhood Pilomyxoid Astrocytoma, Recurrent Childhood Protoplasmic Astrocytoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligoastrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Cerebellar Astrocytoma, Untreated Childhood Cerebral Astrocytoma, Untreated Childhood Diffuse Astrocytoma, Untreated Childhood Fibrillary Astrocytoma, Untreated Childhood Gemistocytic Astrocytoma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliomatosis Cerebri, Untreated Childhood Gliosarcoma, Untreated Childhood Oligoastrocytoma, Untreated Childhood Oligodendroglioma, Untreated Childhood Pilomyxoid Astrocytoma, Untreated Childhood Protoplasmic Astrocytoma, Untreated Childhood Subependymal Giant Cell Astrocytoma, Untreated Childhood Visual Pathway and Hypothalamic Glioma, Untreated Childhood Visual Pathway Glioma
Interventions
18F-fluoro-dihydroxyphenylalanine, Positron emission tomography (PET), Computed tomography (CT), Magnetic resonance imaging
Drug · Procedure
Lead sponsor
Erik Mittra
Other
Eligibility
16 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 28, 2026, 7:32 AM EDT
Completed Phase 1 Interventional

Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors

NCT00100880
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
lenalidomide, perfusion-weighted magnetic resonance imaging, diffusion-weighted magnetic resonance imaging, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 28, 2026, 7:32 AM EDT
Completed Phase 1 Interventional

ABT-751 in Treating Young Patients With Refractory Solid Tumors

NCT00036959
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ABT-751
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 28, 2026, 7:32 AM EDT
Completed Phase 1 Interventional

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

NCT00303940
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
carboplatin, talabostat mesylate, temozolomide, pharmacological study
Drug · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
2 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 28, 2026, 7:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment

NCT00469612
View directory record Official record
Conditions
Myopia
Interventions
NeuroVision's NVC treatment for Low Myopia
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 59 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 28, 2026, 7:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Treating Amblyopia With CureSight

NCT06165705
View directory record Official record
Conditions
Amblyopia
Interventions
CureSight
Device
Lead sponsor
Alaska Blind Child Discovery
Other
Eligibility
2 Years to 20 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 28, 2026, 7:32 AM EDT
Not listed Early Phase 1 Interventional

Combining Wearable Robotic Orthosis With Visual and Haptic Feedback to Enhance the Recovery of Upper Extremity Motor Function and ADL in Persons With Acute SCI

NCT05386537
View directory record Official record
Conditions
SCI - Spinal Cord Injury
Interventions
MyoMo orthosis and VR games, MyoPro robot only, Games only, Control
Combination Product · Device · Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 28, 2026, 7:32 AM EDT
Terminated Not applicable Interventional

Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

NCT01420575
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Visual Decision Aid and Shared Decision Making Model, Usual Care
Behavioral
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
19 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 28, 2026, 7:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study on Visual Function Impairments in Dry Age-related Macular Degeneration

NCT01822873
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 28, 2026, 7:32 AM EDT
Completed No phase listed Observational Results available

Evaluation of Advanced Imaging and Visualization for Clinical Deep Brain Stimulation

NCT06191874
View directory record Official record
Conditions
Deep Brain Stimulation
Interventions
Standard-of-care (SOC) surgery plan, HoloDBS hypothetical surgery plan
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 7:32 AM EDT
Completed Phase 3 Interventional

An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack

NCT00330850
View directory record Official record
Conditions
Migraine, Photophobia, Phonophobia
Interventions
PRO-513
Drug
Lead sponsor
ProEthic Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
16
States / cities
Fairfield, Connecticut • Stamford, Connecticut • Fort Myers, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2007 · Synced Oct 28, 2026, 7:32 AM EDT
Recruiting Not applicable Interventional

Impact of Patient Selected Visual Art in the Hospital Room During Antepartum Admission on Hospital Satisfaction Scores and Patient Experience

NCT06790043
View directory record Official record
Conditions
Pregnancy, Pregnancy Complications, Hospital Environment, Hospitalization, Satisfaction, Patient
Interventions
Patient-selected visual art in hospital room, Routine care
Other
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 28, 2026, 7:32 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

NCT05176717
View directory record Official record
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions
QR-421a, Sham-procedure
Drug · Other
Lead sponsor
Laboratoires Thea
Industry
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 28, 2026, 7:32 AM EDT